Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
Earnings Data
Report Date
May 18, 2026TBA (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
-0.5Last Year’s EPS
0.2Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a balanced picture: strong strategic and commercial progress with the ExuA launch (first-in-class therapy, >100 prescribers, RxConnect-enabled access, and supply readiness) and resilient ADHD performance are meaningful positives. However, near-term financials show declines in net revenue, gross margin pressure (partly from a $600k write-down), higher operating spend for launch, a negative adjusted EBITDA, and a substantial reported net loss driven largely by an $8.2M non-cash derivative warrant loss. Early ExuA metrics are encouraging but limited by short launch duration and weather-related field disruption; cash levels are adequate but have declined modestly. Overall, positives around product launch and access are counterbalanced by near-term financial headwinds and potential generic risk.Company Guidance
Commercial Launch of ExuA — First-in-Class 5-HT1A Agonist
Launched ExuA (first and only FDA-approved 5-HT1A agonist for MDD); commercial launch underway with early commercial activity and multi-channel promotional plan.
Early Prescription and Prescriber Adoption
Over 100 doctors have prescribed ExuA and scripts have been written from 27 states in the first ~30 days; first refills already appearing and early patient feedback reported as positive and well tolerated.
RxConnect Driven Access and Coverage
Aytu RxConnect platform supporting patient access (caps out-of-pocket at $50 for commercially insured), guiding payer contracting that currently covers ~60% of commercially insured MDD patients; RxConnect dispenses ~85% of branded ADHD prescriptions, demonstrating distribution/patient channel strength.
ADHD Portfolio Resiliency
ADHD net revenue of $13.2M for the quarter, only a slight decrease from prior year ($13.8M, down ~4.3%) and essentially flat sequentially versus Q1, despite Salesforce reprioritization and recent ANDA entry by Teva.
Pediatric Revenue Sequential Improvement
Pediatric portfolio net revenue increased sequentially from $0.715M in Q1 to $1.7M in Q2 (approximately +138% sequential), indicating stabilization after prior-quarter returns reduction.
Launch Spend Efficiency
Initial ExuA launch budget reduced from $10M to under $8M due to execution efficiencies; one-time launch costs estimated ~ $3M of the ~$8M.
Supply Readiness and Scalability
Management reports adequate supply and API/components on hand at contract manufacturer to scale substantially beyond initial production runs if demand exceeds expectations.
AYTU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AYTU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 03, 2026 | $2.62 | $2.35 | -10.31% |
Nov 13, 2025 | $2.06 | $2.09 | +1.46% |
Sep 23, 2025 | $2.51 | $2.06 | -17.93% |
May 14, 2025 | $1.35 | $2.59 | +91.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aytu BioScience Inc (AYTU) report earnings?
Aytu BioScience Inc (AYTU) is schdueled to report earning on May 18, 2026, TBA (Confirmed).
What is Aytu BioScience Inc (AYTU) earnings time?
Aytu BioScience Inc (AYTU) earnings time is at May 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AYTU EPS forecast?
AYTU EPS forecast for the fiscal quarter 2026 (Q3) is -0.5.